Cargando…
Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
OBJECTIVES: To determine the relationship between treatment frequency with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes in eyes with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO) in US clinical practice. METHODS: Stud...
Autores principales: | Modi, Yasha S., Goduni, Lediana, Moini, Hadi, Gibson, Andrea, Boucher, Nick, Lucas, Genevieve, Dhoot, Dilsher S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630437/ https://www.ncbi.nlm.nih.gov/pubmed/37156863 http://dx.doi.org/10.1038/s41433-023-02527-7 |
Ejemplares similares
-
Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion
por: Modi, Yasha S., et al.
Publicado: (2021) -
Perifoveal Microcirculation in Macular Oedema with Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2012) -
Clinical characteristics of branch retinal vein occlusion with increased retinal haemorrhage during treatment for macular oedema
por: Lee, You Hyun, et al.
Publicado: (2020) -
Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014) -
A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)